Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
El Resumen Visual
¿Realmente existen diferencias entre los pacientes con enfermedades renales raras de otras causas de ERC?
Veamos este resumen visual creado por el miembro de la facultad NephEdC, Brian Rifkin, el cual activa el RaDaR hacia las enfermedades renales raras.
Are patients with rare kidney diseases different from other CKD? Check out the beautiful VAs by NSMC faculty Brian Rifkin and Cristina Popa
New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) February 9, 2024
✳️10 tweets #NephJC catch-up ✳️
✴️Let’s recap the 2024 KDIGO Lupus Nephritis Guidelines!@BradRovin @AyuobIsabelle @meg21212 @cellotonelli @Gordon7Craig#KDIGO2024
❣️Didn’t get to join the 🐺pack for this one, no worries we’ll help you wolf it down 🥩! pic.twitter.com/Xg8NdWdH23
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Yet another new medication class for use in the RAAS cascade. BI 690517, an aldosterone synthase inhibitor, has been shown to significantly reduce proteinuria with or without empagliflozin. VA by Brian Rifkin.
TenTweetNephJC on X. Natriuresis guidance for intensification of diuretics is one strategy to PUSH decongestion in patient’s with acute heart failure.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) October 5, 2023
Adequate decongestion to prevent rehospitalization & excess mortality are the goals when treating HF. So, why do we fail so often?
This week we look at natriuresis guided diuretic therapy in hospitalized HF patients.
✳️10 tweets #NephJC catch-up ✳️ pic.twitter.com/PjDKcscTOV
If you missed the latest NephJC discussion, at least read the highlights here.
You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) December 1, 2022
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/n8dcopDLPT
